The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

BACKGROUND: Both anlotinib and programmed death 1 (PD-1) monoclonal antibody (mAb) have been approved for the third line treatment of metastatic non-small cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Chongya, Zhang, Xiaoling, Ren, Lulu, You, Liangkun, Pan, Qin, Pan, Hongming, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927598/
https://www.ncbi.nlm.nih.gov/pubmed/33680942
http://dx.doi.org/10.3389/fonc.2020.619010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927598/
https://www.ncbi.nlm.nih.gov/pubmed/33680942
http://dx.doi.org/10.3389/fonc.2020.619010

Ejemplares similares